Physician profile
Mark Corazza
NPI 1508808676
$629.26
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $24.11 · 2021: $113 · 2022: $37.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $443.25 | 2019 | |
| Supernus Pharmaceuticals, INC. | $127.90 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $35.27 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $11.91 | 2020 | |
| Greenwich Biosciences, INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Corazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.